Overexpression of SLC25A38 protein on acute lymphoblastic leukemia cells

Chen,Huaying; Lu,Quanyi; Zhang,Yunwu; Zhang,Cuilin; Zhang,Han; Xu,Huaxi

doi:10.3892/ol.2014.1947

Overexpression of SLC25A38 protein on acute lymphoblastic leukemia cells

Authors:
- Huaying Chen
- Quanyi Lu
- Yunwu Zhang
- Cuilin Zhang
- Han Zhang
- Huaxi Xu
View Affiliations

Affiliations: Department of Hematology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Hematology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, P.R. China, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, College of Medicine, P.R. China
Published online on: March 7, 2014 https://doi.org/10.3892/ol.2014.1947
Pages: 1422-1426

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

SLC25A38 is a recently identified protein that belongs to the mitochondrial solute carrier family, SLC25. Previous studies have shown that it is a pro‑apoptotic protein, which regulates intrinsic caspase‑dependent apoptosis. In order to clarify the effect of SLC25A38 protein expression on acute lymphoblastic leukemia (ALL) cells, we detected the expression of SLC25A38 in various cell lines (RPMI 8226, U266, Molt‑4 and Jurkat) by western blot analysis. The results indicate that SLC25A38 is highly expressed in the four cell lines. Among 55 leukemia patients (adult, n=32 and infant, n=23), a high expression of SLC25A38 protein was observed in seven infant (7/23, 30.4%) and 15 adult (15/32, 46.9%) ALL patients. Two adult ALL patients that were positive for SLC25A38 were analyzed and the level of SLC25A38 significantly reduced or disappeared following combined chemotherapy, however, reappeared upon ALL recurrence. The expression level was identified to be associated with the proportion of blast cells in the bone marrow. Additionally, SLC25A38 and Notch1 were co‑expressed in the four cell lines and the ALL patient samples. The present results show that expression of SLC25A38 is a common feature of ALL cells and may be a novel biomarker for diagnosis, as well as a potential therapeutic target for ALL.

View Figures

View References

1	Barrett AJ, Horowitz MM, Pollock BH, et al: Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med. 331:1253–1258. 1994. View Article : Google Scholar
2	Schroeder H, Gustafsson G, Saarinen-Pihkala UM, et al: Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countries. Bone Marrow Transpl. 23:555–560. 1999. View Article : Google Scholar
3	McNeil DE, Coté TR, Clegg L and Mauer A: SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol. 39:554–557. 2002. View Article : Google Scholar : PubMed/NCBI
4	Bassan R: Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia. Haematologica. 90:12992005.PubMed/NCBI
5	Pui CH and Evans WE: Treatment of actue lymphoblastic leukemia. N Engl J Med. 354:166–178. 2006. View Article : Google Scholar : PubMed/NCBI
6	Pui CH, Robison LL and Look AT: Acute lymphoblastic leukemia. Lancet. 371:1030–1043. 2008. View Article : Google Scholar : PubMed/NCBI
7	Pullarkat V, Slovak ML, Kopecky KJ, et al: Impact of cytogenetics on the outcome of adult actue lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 111:2563–2572. 2008. View Article : Google Scholar : PubMed/NCBI
8	Marks DI, Paietta EM, Moorman AV, et al: T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytpgenetics, and outcome from the large randomized prospective trial (UKALLXII/ECOG 2993). Blood. 114:5136–5145. 2009. View Article : Google Scholar
9	Pui CH, Pei D, Sandlund JT, et al: Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 24:371–382. 2009.
10	Hediger MA, Romero MF, Peng JB, et al: The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflugers Arch. 447:465–468. 2004. View Article : Google Scholar
11	Palmieri F: The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Arch. 447:689–709. 2004. View Article : Google Scholar : PubMed/NCBI
12	Pebay-Peyroula E, Dahout-Gonzalez C, Kahn R, et al: Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside. Nature. 426:39–44. 2003. View Article : Google Scholar : PubMed/NCBI
13	Haitina T, Lindblom J, Renström T and Fredriksson R: Fourteen novel human members of mitochondrial solute carrier family 25 (SLC25) widely expressed in the central nervous system. Genomics. 88:779–790. 2006. View Article : Google Scholar : PubMed/NCBI
14	Guernsey DL, Jiang H, Campagna DR, et al: Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet. 41:651–653. 2009. View Article : Google Scholar
15	Bergmann AK, Campagna DR, Mcloughlin EM, et al: Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 54:273–278. 2010.
16	Kannengiesser C, Sanchez M, Sweeney M, et al: Missense SLC25A38 variations play an important role in autosomal recessive inherited sideroblastic anemia. Haematoligica. 96:33242011.
17	Atamna H: Heme, iron, and the mitochondrial decay of ageing. Ageing Res Rev. 3:303–318. 2004. View Article : Google Scholar : PubMed/NCBI
18	Ryter SW and Tyrrell RM: The heme synthesis and degradation pathways: role in oxidant sensitivity. Heme oxygenase has both pro- and antioxidant properties. Free Radical Biol Med. 28:289–309. 2000. View Article : Google Scholar
19	Leong KG and Karsan A: Recent insights into the role of Notch signaling in tumorigenesis. Blood. 107:2223–2233. 2006. View Article : Google Scholar : PubMed/NCBI
20	Aster JC, Blacklow SC and Pear WS: Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol. 223:262–273. 2011. View Article : Google Scholar : PubMed/NCBI
21	Kanamori E, Itoh M, Tojo N, et al: Flow cytometric analysis of Notch1 and Jagged1 expression in normal blood cells and leukemia cells. Exp Ther Med. 4:397–400. 2012.PubMed/NCBI
22	Mansour MR, Sulis ML, Duke V, et al: Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol. 27:4352–4356. 2009. View Article : Google Scholar
23	Zhang H, Zhang YW, Chen Y, et al: Appoptosin is a novel pro-apoptotic protein and mediates cell death in neurodegeneration. J Neurosci. 32:15565–15576. 2012. View Article : Google Scholar : PubMed/NCBI
24	Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 33:451–458. 1976. View Article : Google Scholar : PubMed/NCBI
25	Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 114:937–951. 2009. View Article : Google Scholar
26	Ferrando AA and Look AT: Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol. 37:381–395. 2000. View Article : Google Scholar
27	Ferrando AA, Neuberg DS, Staunton J, et al: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 1:75–87. 2002. View Article : Google Scholar : PubMed/NCBI
28	Soulier J, Clappier E, Cayuela JM, et al: HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 106:274–286. 2005. View Article : Google Scholar : PubMed/NCBI
29	Ferrando AA, Armstrong SA, Neuberg DS, et al: Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 102:262–268. 2003. View Article : Google Scholar : PubMed/NCBI
30	Aifantis I, Raetz E and Buonamici S: Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol. 8:380–390. 2008. View Article : Google Scholar : PubMed/NCBI
31	Budhu A, Ji J and Wang XW: The clinical potential of microRNAs. J Hematol Oncol. 3:372010. View Article : Google Scholar
32	Fernando TR, Rodriguez-Malave NI and Rao DS: MicroRNAs in B cell development and malignancy. J Hematol Oncol. 5:72012. View Article : Google Scholar : PubMed/NCBI
33	Whitehead KA, Langer R and Anderson DG: Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 8:129–138. 2009. View Article : Google Scholar : PubMed/NCBI
34	Yin L, Velazquez OC and Liu ZJ: Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol. 80:690–701. 2010. View Article : Google Scholar : PubMed/NCBI
35	Breit S, Stanulla M, Flohr T, et al: Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood. 108:1151–1157. 2006. View Article : Google Scholar
36	Weng AP, Ferrando AA, Lee W, et al: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 306:269–271. 2004. View Article : Google Scholar : PubMed/NCBI
37	Aster JC, Pear WS and Blacklow SC: Notch signaling in leukemia. Annu Rev Pathol. 3:587–613. 2008. View Article : Google Scholar
38	Zou J, Li P, Lu F, et al: Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol. 6:32013. View Article : Google Scholar : PubMed/NCBI